Eosinophil cationic protein: Is it useful in asthma? A systematic review

Koh, Gerald Choon‐Huat; Shek, Lynette Pei‐Chi; Goh, Daniel Yam Thiam; Bever, Hugo Van; Koh, David

doi:10.1016/j.rmed.2006.08.012

Cited by 148 publications

(156 citation statements)

References 62 publications

(110 reference statements)

Supporting

Mentioning

141

Contrasting

Unclassified

Order By: Relevance

“…Recently, serum ECP is being widely studied and investigated to conclude it as a valuable marker for diagnosis and prognosis of bronchial asthma 11,12 . Eosinophil count cannot differentiate between responders and non responders to asthma therapy which correlate with our study 17 .…”

Section: Discussionmentioning

confidence: 99%

“…ECP is a guide to tailing down inhaled corticosteroid therapy and assessment of compliance to most forms of anti-inflammatory therapies in asthma and guiding the tapering of inhaled corticosteroid in stabilized asthmatics 20 .…”

Section: Discussionmentioning

confidence: 99%

“…On the other hand, serum ECP correlate more than eosinophil count in poor control of asthma and higher ECP level are found in uncontrolled asthma 10 . Serum ECP level also can be used to estimate the short term risk of deterioration and the need for corticosteroid treatment in cases of mild and moderate allergic asthma, thus it may have a useful role to play as a control parameter in asthma guideline 11 .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Serum Eosinophilic cationic protein (ECP) as an effective biological marker to monitor therapy in bronchial asthma patients.

Begum¹,

Sattar

et al. 2011

Bangladesh J Med Microbiol

View full text Add to dashboard Cite

Clinically diagnosed bronchial asthma patients comprising of new cases, on therapy or follow up were enrolled for this study to see if the new biological marker Eosinophilic cationic protein (ECP) can be used as a more precise marker to monitor therapy than the presently used conventional ones like FEV1% predicted, PEFR, and Circulating eosinophil (C.E) count. Out of 70 bronchial asthma patients, 30 intermittent, 4 mild persistent, 24 moderate persistent and 12 severe persistent asthma patients were included, while 45 cases were enrolled for follow up. Serum level of eosinophil granular protein, Eosinophilic cationic protein (ECP) was measured in relation to changes in their forced expiratory volume in 1st second (FEV1% predicted) and Circulating Eosinophil count (%) before and after therapy in 45 follow up patients on asthma therapy. In this study, it was observed that C.E count (%) and FEV1% predicted were not decreased significantly and serum eosinophilic cationic protein (ECP) decreased significantly (p<0.001) after asthma therapy. Thus, serum ECP level can be used as a biological marker than other conventionally used marker (FEV1, C.E count) to monitor therapeutic efficacy in bronchial asthma patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serum Eosinophilic cationic protein (ECP) as an effective biological marker to monitor therapy in bronchial asthma patients.

Begum¹,

Sattar

et al. 2011

Bangladesh J Med Microbiol

View full text Add to dashboard Cite

show abstract

“…A possible explanation for this could be that ECP may cause extensive injuries to the lungs and organ epithelium, airway epithelium shedding, and mucous plug in bronchus, which could consequently lead to airway hyper-responsiveness and ventilation disorders (Koh et al 2007). SABA is able to inhibit the aggregation and activation of eosinophil and down-regulate IgE production and the secretion of ET-1 in the airways, thereby decreasing ECP release and suppressing the synthesis of nitric oxide (Walters andWalters 2000: Naureckas et al 2005;Chipps et al 2006).…”

Section: Discussionmentioning

confidence: 99%

“…These include airway epithelial injury and shedding, thereby inducing mast cells to release histamine. Consequently, these effects may lead to the development of airway hyper-responsiveness and obstruction (Koh et al 2007;Bystrom et al 2012). On the bright side, Serum ECP is a specific Eosinophil marker that reflects its activation status (higher ECP means higher Eosinophil activity) (Koh et al 2007;Bystrom et al 2011).…”

Section: Introductionmentioning

confidence: 99%

Serum Eosinophil Cationic Protein Is a Useful Marker for Assessing the Efficacy of Inhaled Corticosteroid Therapy in Children with Bronchial Asthma

Guo

Sun

Wang

et al. 2017

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Bronchial asthma (BA) is a chronic inflammatory disorder of airways for which the effective therapies include inhaled corticosteroids (ICS) and short-acting β 2-adrenoreceptor agonist (SABA). Serum eosinophil cationic protein (ECP) has been reported to reflect the degree of airway inflammation. We, therefore, explored the implication of serum ECP in assessing the efficacy of ICS therapy in BA children. Our prospective randomized control study enrolled 126 BA children and 78 healthy children (the control group). The BA patients were randomly assigned as two groups; 59 children were treated with ICS, twice a day, for three months and 67 patients received SABA inhalation only if necessary. After the 3-month therapy, the serum levels of ECP, endothelin-1, and nitric oxide and the eosinophil percentage (EOS%) in induced sputum were significantly lower in the ICS group, compared with the SABA group, but were still higher than the control group (all P < 0.05). The forced expiratory volume (FEV1%pred) and forced vital capacity (FEV1/FVC) were improved to the levels of the control group after therapy. Pearson correlation analysis presented that higher serum ECP levels were associated with higher EOS% in serum and with lower pulmonary function indices (FEVl%pred and FEV1/FVC). Importantly, the ICS group exhibited higher quality of life scores and lower symptom scores compared with the SABA group (all P < 0.05). ROC results revealed the diagnostic efficiency of serum ECP levels on the efficacy of ICS. In conclusion, measuring serum ECP levels is helpful for assessing the efficacy of ICS therapy in BA children.

show abstract

Genetic Associations of Circulating Cardiovascular Proteins With Gestational Hypertension and Preeclampsia

Schuermans,

Truong,

Ardissino

et al. 2024

JAMA Cardiol

View full text Add to dashboard Cite

ImportanceHypertensive disorders of pregnancy (HDPs), including gestational hypertension and preeclampsia, are important contributors to maternal morbidity and mortality worldwide. In addition, women with HDPs face an elevated long-term risk of cardiovascular disease.ObjectiveTo identify proteins in the circulation associated with HDPs.Design, Setting, and ParticipantsTwo-sample mendelian randomization (MR) tested the associations of genetic instruments for cardiovascular disease–related proteins with gestational hypertension and preeclampsia. In downstream analyses, a systematic review of observational data was conducted to evaluate the identified proteins’ dynamics across gestation in hypertensive vs normotensive pregnancies, and phenome-wide MR analyses were performed to identify potential non-HDP–related effects associated with the prioritized proteins. Genetic association data for cardiovascular disease–related proteins were obtained from the Systematic and Combined Analysis of Olink Proteins (SCALLOP) consortium. Genetic association data for the HDPs were obtained from recent European-ancestry genome-wide association study meta-analyses for gestational hypertension and preeclampsia. Study data were analyzed October 2022 to October 2023.ExposuresGenetic instruments for 90 candidate proteins implicated in cardiovascular diseases, constructed using cis-protein quantitative trait loci (cis-pQTLs).Main Outcomes and MeasuresGestational hypertension and preeclampsia.ResultsGenetic association data for cardiovascular disease–related proteins were obtained from 21 758 participants from the SCALLOP consortium. Genetic association data for the HDPs were obtained from 393 238 female individuals (8636 cases and 384 602 controls) for gestational hypertension and 606 903 female individuals (16 032 cases and 590 871 controls) for preeclampsia. Seventy-five of 90 proteins (83.3%) had at least 1 valid cis-pQTL. Of those, 10 proteins (13.3%) were significantly associated with HDPs. Four were robust to sensitivity analyses for gestational hypertension (cluster of differentiation 40, eosinophil cationic protein [ECP], galectin 3, N-terminal pro–brain natriuretic peptide [NT-proBNP]), and 2 were robust for preeclampsia (cystatin B, heat shock protein 27 [HSP27]). Consistent with the MR findings, observational data revealed that lower NT-proBNP (0.76- to 0.88-fold difference vs no HDPs) and higher HSP27 (2.40-fold difference vs no HDPs) levels during the first trimester of pregnancy were associated with increased risk of HDPs, as were higher levels of ECP (1.60-fold difference vs no HDPs). Phenome-wide MR analyses identified 37 unique non-HDP–related protein-disease associations, suggesting potential on-target effects associated with interventions lowering HDP risk through the identified proteins.Conclusions and RelevanceStudy findings suggest genetic associations of 4 cardiovascular disease–related proteins with gestational hypertension and 2 associated with preeclampsia. Future studies are required to test the efficacy of targeting the corresponding pathways to reduce HDP risk.

show abstract

Eosinophil cationic protein: Is it useful in asthma? A systematic review

Abstract: Despite its limitations, ECP remains potentially useful in asthma management. Future research on ECP should focus on using serial measurements and combining it with other markers of asthma which may increase its clinical usefulness.

Cited by 148 publications

References 62 publications

Serum Eosinophilic cationic protein (ECP) as an effective biological marker to monitor therapy in bronchial asthma patients.

Serum Eosinophilic cationic protein (ECP) as an effective biological marker to monitor therapy in bronchial asthma patients.

Serum Eosinophil Cationic Protein Is a Useful Marker for Assessing the Efficacy of Inhaled Corticosteroid Therapy in Children with Bronchial Asthma

Genetic Associations of Circulating Cardiovascular Proteins With Gestational Hypertension and Preeclampsia

Contact Info

Product

Resources

About